Principia Biopharma is conducting a phase three randomized, double-blind study of rilzabrutinib (previously referred to as PRN1008), and oral BTK inhibitor. They are looking to enroll patients with persistent or chronic ITP who are at least 12 years of age. Eligible patients must have an average platelet count of <30,000/μL on two counts (with no count higher than <35,000/μL) at least 5 days apart in the 14 days before treatment begins. The double-blind treatment period is 12-24 weeks depending on platelet response, followed by a 28-week open label period. Patients who respond to rilzabrutinib may enter a long term-extension. After the last dose of rilzabrutinib there will be a 4-week safety follow-up visit.
Argentina, Austria, Australia, Chile, France, Germany, Hungary, Isreal, Italy, Norway, Poland, Russian Confederation, Singapore, South Korea, Spain, Thailand, Ukraine, UK, and the USA.
https://clinicaltrials.gov/ct2/show/NCT04562766
Recruiting
